Diagnosis and treatment progress of follicular lymphoma
10.3760/cma.j.issn.1009-9921.2019.12.003
- VernacularTitle: 滤泡淋巴瘤诊治进展
- Author:
Bing XU
1
;
Zhijuan LIN
Author Information
1. Department of Hematology, the First Affiliated Hospital of Xiamen University, Xiamen 361003, China
- Publication Type:Review
- Keywords:
Lymphoma, follicular;
Genetics;
Prognosis;
Molecular targeted therapy
- From:
Journal of Leukemia & Lymphoma
2019;28(12):713-715
- CountryChina
- Language:Chinese
-
Abstract:
Follicular lymphoma (FL) is the most common indolent lymphoma. With the improvement of disease awareness and the introduction of various novel drugs, the 5-year overall survival rate has been more than 90% for the majority of FL patients. However, certain subgroups of FL patients, especially patients who progressed within 24 months after starting front-line therapy, still have worse outcome. This article reviews the progress in genetics, prognostic factors and treatment options of FL that reported at the 61st American Society of Hematology Annual Meeting 2019.
